Extensive-stage small-cell lung cancer

Research output: Contribution to journalReview articlepeer-review


Extensive-stage small-cell lung cancer (ES-SCLC) continues to be a difficult management issue. While response rates to therapy are relatively high, durable responses are rare, and long-term survival rates are dismal. Although many attempts have been made to develop new therapies, cisplatin-based combination chemotherapy remains the mainstay in the management of these patients. In this review we highlight recent developments in the treatment and management of this malignancy, and discuss future prospects in treatment.

Original languageEnglish (US)
Pages (from-to)164-175
Number of pages12
JournalSeminars in surgical oncology
Issue number3
StatePublished - Oct 22 2003


  • Cisplatin
  • Etopiside
  • Small-cell lung cancer
  • Topotecan

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'Extensive-stage small-cell lung cancer'. Together they form a unique fingerprint.

Cite this